



Harm Reduction

(An Introduction and Housing for Health Policy Statement)

Los Angeles Department of Health Services
(DHS) Quarantine and Isolation (QI) Medical Shelters


Purpose

- To ensure that all staff are familiar with Harm Reduction principles and practices and understand how to apply them in the care of clients at the DHS' QI Medical Shelters.

- Harm Reduction strategies aim to reduce the harms associated with certain behaviors such as smoking, substance use, sex, treatment non-adherence, domestic violence, or other behaviors related to mental health or characterological disorders

Background

- Defined in the 1980s as an alternative to abstinence-only focused interventions for adults with Substance Use Disorder (SUD)
- Observed that:
 - Many people who used substances were not ready to stop
 - Could be counseled and supported in using in less harmful ways
- Harm Reduction principles are now widely applied in the delivery of trauma-informed, patient-centered care of individuals who engage in a variety of behaviors that may pose risk to themselves or others




1

Purpose

- 1) Outline the management of harm reduction to keep clients at or near baseline consumption and avoid an early exit or emergency room visit due to withdrawal or other substance use or characterological complications
- 2) Ensure all staff are familiar with harm reduction principles/practices and understand how to apply them in the care of clients during QI

2



3

Scope

- Applies to all County employees and contracted management, clinical and non-clinical staff involved with management of supplies, client assessments, or delivery of materials to individuals in quarantine status
- Applies to individuals or clients who are in a County QI Medical Shelter who choose to continue consumption during their stay after reviewing the risks with QI staff

4

Scope

- In-service will cover policies and procedures for:
 - Cannabis
 - Alcohol (ETOH)
 - Opiates
 - Stimulants

5

Harm Reduction: Screening

- Medical intake for all harm reduction will include:
- Substance use/consumption assessment to identify persons at risk of negative psychological impacts or behavioral changes due to consumption
- Assess if client is currently using other substances or in a substance use disorder treatment program

6

Cannabis - Screening

- Questions to ask during intake:
 - Do you currently use alcohol, marijuana or other substances? If so, what kind? How much? How often?
 - What happens when you do not smoke marijuana? Do you use marijuana to self-medicate for anxiety or other psychological concerns?
 - Are you currently in a residential or outpatient treatment program for substance use?

7

Cannabis - Screening

- If a client is not in a program but is open to cessation, resources and on-site support will be made available before offering MAT or other harm reduction supplies
- If a Provider deems Cannabis cessation poses a risk of **adverse medical or psychological affects and client declines** alternative supportive measures, the Provider will prescribe appropriate cannabis allotment

8

Cannabis – Dispensing Guidelines

- General serving provisions
 - Cannabis products can be provided to clients 18 and older who have a valid pre-existing prescription. 21+ do not need prior Rx
 - Consumption on-site only
 - Deliver the product(s) directly to the client
 - Provider must document reason for any Cannabis allotment changes
 - All dispensed Cannabis must be documented in the client's MAR by end of shift

9

Cannabis – Dispensing Guidelines

- Considerations for clients enrolled in or referred by a SUD program include:
 - Supportive environment to help maintain recovery or sobriety
 - Measures to link clients to the ir counselor/program for additional support
 - Cannabis per this protocol (when other measures are not feasible/available)
 - Do not withhold Cannabis for the sole reason a client is actively engaged in a SUD program

10

Cannabis - Dispensing Guidelines

Inhalable: Joint or Vape

	Small Amt of Joint	Part of a Joint ¹	Whole Joint	Vape.. UghUy	Vape.. tteavHv
1x per day	1 joint / 3days	1 joint/ 2days	1 joint/ day	1 vape / 2 weeks	1 vape/ 3 days
2-3x per day	1 joint/ 2 days	1 joint/ day	2 joints/ day	1 vape / week	1 vape/ 2 days
All day	All joint/ day	2 joints/ day	4 joints/ day	1 vape / 2-3 days	1 vape / day

(adjust as needed to individual usage patterns)

¹ 1 joint = ap prox. 1g
.. 1 vape = 1g

11

Cannabis - Dispensing Guidelines

Edibles

	Unsure of Dose	Low Dosage	Medium Dose&e	High Dose*
1x per day	5 mg / day	10 mg / day	30 mg / day	60+ mg/day
2-3x per day	10 mg / day	20-30 mg / day	60-90 mg/ day	120-180+ me: /day
All day		30+ mg/ day	90f.mg/day	180+ mg/day

(adjust as needed to individual usage)

¹ some people use 1000+ mg per occ...

12



Cannabis – Monitoring

- Clients using Cannabis or actively engaged in a SUD program may require more frequent wellness checks
- Consult RN and/or Provider if a client appears altered or presents with behavioral changes

13

ETOH – Screening

- Questions to ask:
 - Do you currently drink alcohol?
 - How much and how often?
 - Have you ever had seizures or "DTs" upon stopping?
 - Have you had other withdrawal symptoms? What kind?
 - Are you currently in a residential or outpatient treatment program for substance use? Name and contact of program?
 - Are you willing to consider a detox/sobering protocol while in the QI Medical Shelter, including medications to prevent or minimize withdrawal symptoms if necessary?

14

ETOH - Screening

- Questions to ask:
 - Moderate-high risk persons are current alcohol consumers PLUS one of the following:
 - Consumption of four or more standard drinks on most days
 - History of withdrawal seizures from benzodiazepines or alcohol
 - History of *Delirium Tremens*
 - Subjective report of experience of alcohol withdrawal symptoms
 - Low risk persons:
 - Absence of any withdrawal history
 - Consumes less than 4 standard drinks daily
 - If client is moderate-high risk and agrees to detox/sobering protocol, gabapentin or chlordiazepoxide will be prescribed appropriately

15

ETOH - Screening

- Provider will order appropriate ETOH allotment and indicate their current SUD treatment program status if applicable:
 - Nursing to notify Community Partner
 - Community Partner logs patient name and alcohol limitations in their tracker
 - For guests at moderate to high risk of withdrawal, Provider shall estimate the client's baseline use, in standard drinks, in chart

16



ETOH – Drink Definitions

- Standard drink definitions
 - 1 standard drink = 12-ounce beer = 9 ounce malt liquor = 5-ounce wine = 1.5-ounce (a "shot") distilled spirit
- Distilled spirits:
 - $\frac{1}{2}$ pint of distilled spirits = 4.5 standard drinks
 - 1 pint of distilled spirits = 8.5 standard drinks
 - A "fifth" of distilled spirits = 17 standard drinks
- Wine
 - 1 table wine bottle = 5 standard drinks
 - 1 3-liter wine box = 20 standard drinks

17

ETOH - Serving

Self reported daily consumption	Max Amount & Frequency	Daily limit
1-3 standard drinks	1-2 standard drinks every 1 hour	3 drinks/day
4-6 standard drinks	2 standard drinks every 2-4 hours	6 drinks/day
7-10 standard drinks	3 standard drinks every 2-4 hours	10 drinks/day
11-15 standard drinks	3 standard drinks every 2-4 hours	15 drinks/day
16-20 standard drinks	4 standard drinks every 2-4 hours	20 drinks/day
>20 standard drinks	Rx at discretion of provider	

18

ETOH - Monitoring

- Moderate-high risk clients/actively engaged in a SUD program may require more frequent wellness checks
- Consult RN and/or Provider if guest appears too intoxicated or presenting with other behavioral concern at any time
- RNs will use the alcohol intoxication scale to objectively support further action such as:
 - Performing additional safety assessment(s)
 - Withhold additional standard drinks for 1 or more hours
 - Increase frequency of wellness checks
 - Reduce total daily limits of alcohol (with consultation)

19

- If client complains of withdrawal discomfort or exhibits physical symptoms of alcohol withdrawal
 - Provide additional drinks (if limit has not been exceeded)
 - Contact RN to perform a withdrawal assessment using SAWS and provide additional standard drinks when necessary if limit is exceeded
 - Consult the Provider if a client exhibits withdrawal symptoms that may require additional medical or pharmacological support

20

ETOH - Documentation

- Provider:** Prescribe ETOH (or other appropriate harm reduction measure)
- Nursing staff: Transcribe orders in MAR
- community Partner:** 1) maintain an alcohol delivery log; 2) document the date, time, and quantity of standard drinks distributed; 3) provide copies of alcohol delivery log to nursing staff at the end of each shift

21

22

Opiates - Screening

- Any person who reduces or discontinues consumption after chronic use is at risk for withdrawal symptoms. Any person who continues consumption is at risk for overdose or death.
- Medical intake will assess:
 - Consumption frequency
 - Risk of opiate withdrawal
 - Enrollment of SUD program
 - Willingness to undergo MAT protocol while at QI

23

24

Opiates - Screening

Questions to ask client upon intake:

- What substances do you use?
- Are you willing to consider a detox/ sobering protocol while at QI, including medications to prevent or minimize withdrawal symptoms and cravings if necessary?
- How frequently and what quantities do you use? When was your last use?
- What substances, and what quantities, do you have with you?
- Do you have safe use supplies with you?
- Do you feel comfortable sharing how you use drugs? (e.g., inject, smoke, snort, booty bump, etc.)

25

Opiates - Screening

Questions to ask client upon intake (continued):

- Do you use any substances in combination with each other, including alcohol?
- Have you considered alternative modes of use? For example, if you normally inject would you be willing to try smoking instead?
- Have you ever overdosed? If yes, please share.
- Have you ever experienced opiate withdrawal? If yes, what were your symptoms?
- If you continue to use opiates while at QI, are you willing to create an Overdose Prevention Plan and consent to wellness checks?

26

Opiates - Screening

• Questions to ask client upon intake (continued):

- If you continue to use opiates while at QI, are you open to calling a friend/ loved one/ member of the medical staff and having them remain on the line with you while you use?
- Are you currently in a residential or outpatient treatment program for substance use? Name and contact of program?
- If client agrees to detox/sobering protocol, buprenorphine/naloxone or buprenorphine will be prescribed.

27

Opiates – Providing Safe Use Supplies

• General provisions:

- Safe use/harm reduction supplies and/or medications for MAT will be ordered by the Provider
- All clients actively using opiates will be provided Narcan and instructed on how to use it
- Deliver the product(s) directly to the client
- Clients will be provided with "Never Use Alone" information

28

Opiates- Providing Safe Use Supplies

- Considerations for guests enrolled in or referred by a SUD program include:
 - Supportive environment to help maintain recovery or sobriety
 - Measures to link clients to their counselor/program for additional support
- Provide harm reduction/safe use supplies per this protocol (when other supportive measures are not feasible or available)

29

Opiates – Monitoring

- Wellness checks will be conducted at a frequency determined and ordered by the Provider
- Consult RN/Provider if guest appears too intoxicated or presenting with other behavioral concern at any time
- Consult RN/Provider for any client with overdose or withdrawal symptoms that may require additional medical or pharmacological support

30



- Provider will prescribe MAT and/or safe use supplies or harm reduction measures
- Nursing staff should transcribe orders in MAR where appropriate
- Clinical staff shall complete an Overdose Prevention Plan with client

31

Opiates - Supply Management

- Clients who are unwilling to undergo MAT/insist on continuing to use unprescribed opiates during QI:
 - Are allowed to do so from their personal supply (must complete an Overdose Prevention Plan)
 - Must consent to frequent wellness checks on a schedule to be determined by the Provider
 - QI will not supply opiates other than Suboxone in the event the client runs out

32

Appell'dbcB-DapartmentofHIIHServices
Hesul'g for Health QI Site Opioid Withdrawal Standing Orders
On-call Provider/Consultant Unit for SUD: 213-288-4090 (24/7)

U Prtrviden wld'ckinwah cfiont over the phone B for 24 h d'lns for days 1-3
Opioid withdrawal does not require any, in.;(Lna datSHsmJII ornting lo ls-ol Ifpallion1011dor10,
opioid r.rwll, or :duse, prcvidr treatm1n t bupnmorphina, maina.

Day 1 Of Bup, tpmn CbxOne(\$ubom:ie)8mg-2mg t lllbsnm subling, UOI)*1.
Re-Part: Mv, up to 4 lim s. or until elif +pmolled withrawal symptom J conw+1.
Day 2: GiveBup ruzitifne-NalOxono8mg-2mg] 2tblfilm,utl fnc: ual chily, Forfim wsOk, if
addit'l cnal symptoms of opioid withdrawal, g11e halftblfilm (4mg - 1 mg qth PRN).

ffp alant,if: no fo wld'nt, al!n! h d y puds through 11 rhdwrwa lwnlawa,c.g.,rGpoffil la:t-
usGpofolds more than 5cbsys,19a rollowabova dosng wU111tuPRN do MS.
can suo MD ort-e211
If anyplanc unrn o.1111 d with mu, PRN elcu (total G31 mg bupnmerphine In d"li)
If cllint d+ vloen +symptom, cf **MY**., opioid withdrawal
If ellant and dorus use afmethadon& within pttor week.

33



- Any person who reduces or discontinues stimulant consumption after chronic use is at risk for stimulant withdrawal symptoms
- Any person who continues stimulant consumption is at risk for overdose or death
 - Medical intake will include a stimulant consumption assessment
- If a client is not in a program but is open to cessation, resources and on-site support will be made available

34

Stimulants - Screening

- Questions to ask client upon intake:
 - What substances do you use?
 - How frequently and what quantities do you use?
When was your last use?
 - What substances, and what quantities, do you have with you?
 - Do you have safe use supplies with you?

35

Stimulants - Screening

- Questions to ask client upon intake:
 - Do you feel comfortable sharing how you use drugs? (e.g. inject, smoke, snort, booty bump, etc.)
 - Do you use any substances in combination with each other, including alcohol?
 - Have you considered alternative modes of use? For example, if you normally inject would you be willing to try smoking instead?
 - Have you ever overdosed? If yes, please share.
 - Have you ever experienced stimulant withdrawal? If yes, what were your symptoms?

36

Stimulants - Screening

- Questions to ask client upon intake:
 - Have you ever experienced stimulant withdrawal? If yes, what were your symptoms?
 - If you continue to use stimulants while at QI, are you willing to create an Overdose Prevention Plan and consent to wellness checks?
 - If you continue to use stimulants while at QI, are you open to calling a friend/loved one/member of the medical staff and having them remain on the line with you while you use?
 - Are you currently in a residential or outpatient treatment program for substance use? Name and contact of program?

37

Stimulants - Providing Safe Use Supplies

- General provisions:
 - Safe use/harm reduction supplies and/or medications for MAT will be ordered by the Provider
 - All clients actively using opiates will be provided Narcan and instructed on how to use it
 - Deliver the product(s) directly to the client
 - Clients will be provided with "Never Use Alone" information
- Unlike with OUD and AUD, there is not a currently approved or accepted protocol for stimulant use detoxification. Management is symptom based only.

38



39

Stimulants – Monitoring

- Wellness checks will be conducted at a frequency determined and ordered by the Provider
 - Clinical staff will enter guest rooms using master keys if a client does not respond to wellness checks.
- Consult RN/Provider if guest appears too intoxicated or presenting with other behavioral concern at any time
- Consult RN/Provider for any client with overdose or withdrawal symptoms that may require additional medical or pharmacological support

40

Stimulants – Documentation


- Provider will prescribe MAT and/or safe use supplies or harm reduction measures
- Nursing staff should transcribe orders in MAR where appropriate
- Clinical staff shall complete an Overdose Prevention Plan with client

41

Stimulants - Supply Management

- Clients who are unwilling to undergo MAT/insist on continuing to use unprescribed stimulants during QI:
 - Are allowed to do so from their personal supply (must complete an Overdose Prevention Plan) although strongly discouraged since there is no real risk of withdrawal
 - Must consent to frequent wellness checks on a schedule to be determined by the Provider
 - Protocols for withdrawal/overdose will be followed when applicable

42



43

Harm Reduction – Supply Management

- Harm reduction stock intended for patient use will be stored in a locked cabinet
- Stock is managed by Clinical staff
- Stock **will** include sharps containers, syringes, alcohol prep pads, sterile water, cookers, cotton balls, tourniquets, fentanyl test strips, and naloxone
- All clients actively using opiates will be provided with naloxone and instructed about its use

44

Harm Reduction: Privacy


- Information about an individual guest request(s) for substances or substance consumption, or behaviors thereof, should be treated with the same level of integrity as patient health information

45

Harm Reduction – Quarantine Exit

- All precautions shall be taken to avoid dangerous activities for clients on day of exit (e.g., driving, riding a bicycle)
- Staff cannot provide additional Cannabis/ETCH products to persons "to go" upon exiting quarantine for any reason
- Clients undergoing medically assisted treatment will be provided a take-home supply of medications per protocol

46



- Complete the Harm Reduction competency check using this link: <https://www.surveymonkey.com/r/gCK23X8>
- A copy of all the Harm Reduction policy & procedures will be provided for assistance

47

THANK YOU!

48